WHO and experts prioritize vaccines, diagnostics and innovative vector control tools for Zika R&D

After a three-day consultation on Zika research and development, international experts, convened by WHO, have agreed on top priorities to advance R&D for Zika medical products. The following tools were prioritized as the most viable options to help fight the spread of Zika virus in the immediate future: Multiplex tests for ‘flaviviruses’ (viruses related to Zika, such as dengue, chikungunya), in addition to more traditional tests; protective vaccines based on killed virus (or other non-live) preparations for women of childbearing age; and innovative vector control tools that reduce the mosquito population. “Zika virus induces a mild and mostly harmless infection in the majority of patients,” indicated Dr Marie-Paule Kieny, Assistant Director-General in charge of R&D at WHO. “For that reason medicines to treat it seem less of a priority at this stage. The most pressing need is the development of diagnostic and preventive tools to address the current R&D gap and protect pregnant women and...